Today: 11 June 2026
Browse Category

Pharmaceutical Industry 11 December 2025 - 20 December 2025

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences shares closed at $124.29 on Dec. 19, up 2.32%, after President Trump announced a drug pricing deal with nine major firms, including Gilead. The agreement includes Medicaid price cuts, cash-pay discounts via TrumpRx.gov, and a three-year tariff exemption tied to increased U.S. manufacturing. Gilead expects the financial impact to be manageable in 2026.
20 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, amid heavy trading and technical breakout signals. The move follows recent investor conference appearances and ongoing focus on late-stage neuromuscular and cardiovascular drug programs. As of September 30, the company reported $563.3 million in cash and a Q3 net loss of $40.7 million.
20 December 2025
·
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, offering $14.50 per share. Amicus stock jumped roughly 30% to $14.18 on heavy volume, trading just below the bid as investors assess deal closure risks. Both boards approved the transaction, with closing targeted for Q2 2026 pending shareholder and regulatory approvals.
20 December 2025
·····
AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie shares closed at $226.82, up 1.80% Friday, then slipped a penny in after-hours trading. Trading volume surged to about 17.4 million shares as investors reacted to White House drug-pricing deals. AbbVie was not among the nine drugmakers that agreed to new pricing terms and remains in talks with the administration, according to Reuters.
20 December 2025
··
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, paying $14.50 per share—a 33% premium to Amicus’ prior close. The transaction, approved by both boards, is expected to close in Q2 2026 pending shareholder and regulatory approvals. BioMarin will fund the deal with cash and $3.7 billion in debt financing. The acquisition adds two rare-disease drugs and a Phase 3 pipeline asset.
19 December 2025
····
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer shares traded near $25.04 midday Friday after a volatile week, holding steady despite new policy headlines and a guidance reset. The company issued 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. Pfizer also reported positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
19 December 2025
···
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK said Thursday it bought 235,000 shares on Dec. 17 as part of its ongoing buyback, bringing total repurchases since Sept. 30 to over 14 million shares. GSK’s ADR traded at $48.71 in New York, down 0.13%. The company reported 239.6 million shares now held in treasury. Earlier this week, the FDA approved GSK’s Exdensur for severe asthma.
18 December 2025
··
Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer shares fell 3.4% to $25.53 Wednesday after the company cut its 2025 revenue forecast to about $62 billion and issued 2026 guidance below analyst expectations. Pfizer now projects 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. COVID-19 product sales are expected to drop to $5 billion in 2026. No share repurchases are planned for 2025 or 2026.
17 December 2025
···
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics shares fell 9% to $79.44 on December 16, 2025, after UBS initiated coverage at Neutral with a $95 target, citing valuation concerns. The stock had surged about 75% year-to-date. No major clinical or regulatory news drove the drop. Trading volume reached approximately 1.27 million shares.
16 December 2025
···
AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie shares fell 2.2% to $222.44 as of 17:54 UTC Tuesday after Bank of America cut its price target to $233 from $248 and kept a Neutral rating. The stock had traded near the top of its 52-week range before the drop. Analysts remain divided, with consensus 12-month targets ranging from $190 to $289. No major company-specific news drove the decline.
16 December 2025
··
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics shares traded near $22 on Dec. 16, 2025, valuing the company at roughly $2–$3 billion. The company expects to close a $291.4 million convertible debt exchange on Dec. 18, shifting debt maturities and adding $31.6 million in cash. ELEVIDYS remains under scrutiny after the FDA added a boxed warning for serious liver risks in November.
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 on December 16 after Bank of America upgraded the stock to Buy and raised its price target to $61, citing confidence in the company’s R&D pipeline. The board also increased the quarterly dividend to $0.63 per share, payable February 2, 2026, marking a 1.6% annual increase and the 17th consecutive yearly hike.
16 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 Monday after Bank of America upgraded the stock to Buy and raised its price target to $61. The stock added another 0.6% in after-hours trading. Volume in extended trading reached about 1.25 million shares. Analysts cited the company’s R&D pipeline and upcoming catalysts as key drivers.
16 December 2025
··
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer shares traded at $25.85 as of 12:08 UTC Monday, unchanged from Friday’s close. The company will hold a conference call Tuesday morning to provide full-year 2026 financial guidance. Pfizer’s board declared a $0.43 first-quarter 2026 dividend, marking its 349th consecutive quarterly payout. Market cap stands near $147 billion.
15 December 2025
····
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray for adults with paroxysmal supraventricular tachycardia, marking the first new U.S. PSVT treatment in over 30 years. The company targets retail availability in Q1 2026. Shares showed sharp volatility after the announcement. Milestone scheduled an investor call for December 15 to discuss launch plans.
15 December 2025
·
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL shares closed Friday at A$183.93, up 2.86% on the day but down 0.85% for the week. The company reported five-year data for its hemophilia B gene therapy HEMGENIX, showing 94% of patients remained free from continuous treatment. Investors also weighed scrutiny of CSL Seqirus vaccine deals and the ongoing A$750 million buyback.
14 December 2025
··
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

European regulators on Dec. 12 recommended refusing marketing authorization for Anavex’s Alzheimer’s drug Blarcamesine, citing insufficient evidence of effectiveness, unresolved safety issues, and quality concerns. The EMA said Anavex may request re-examination within 15 days. Anavex shares, already volatile, moved sharply in early trading.
12 December 2025
·
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK shares traded near $48.88 Friday as the company reported key regulatory wins. The EMA’s CHMP backed expanding Arexvy’s RSV vaccine to all adults 18+ in Europe, with a final decision expected in February. The FDA also approved Blujepa (gepotidacin) for gonorrhea, marking the first new antibiotic class for the infection in decades. Analyst consensus sees Arexvy sales rising to £1.17 billion by 2031.
12 December 2025
··
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer shares traded at $25.66 on December 11, 2025, following an FDA approval for PADCEV plus Keytruda in bladder cancer and a new GLP‑1 weight-loss deal. The company declared a $0.43 per-share dividend for Q4, marking its 348th consecutive quarterly payout. Pfizer’s annualized yield stands at about 6.7%. Consensus 2025 EPS is $3.1–$3.2, giving a forward P/E near 8.
11 December 2025
·
1 … 4 5 6 7 8 9

Stock Market Today

  • Leverage Shares to List SpaceX 3x Leverage ETP on London Stock Exchange
    June 10, 2026, 8:44 PM EDT. Leverage Shares will list its SpaceX 3x Leverage Exchange Traded Product (ETP) on the London Stock Exchange on June 12th, the company announced on June 11th. The ETP offers investors the ability to gain triple leveraged exposure to SpaceX shares, allowing for amplified returns relative to the underlying stock's daily performance. This listing adds to the growing range of leveraged products available on the LSE, catering to investors seeking enhanced market participation.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Go toTop